CONMED (Nasdaq: CNMD) reported earnings on July 29. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), CONMED met expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue increased slightly. Non-GAAP earnings per share stayed the same. GAAP earnings per share shrank.

Gross margins grew, operating margins dropped, net margins shrank.

Revenue details
 CONMED booked revenue of $193.0 million. The three analysts polled by S&P Capital IQ wanted to see revenue of $193.6 million on the same basis. GAAP reported sales were 1.0% higher than the prior-year quarter's $189.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at $0.43. The four earnings estimates compiled by S&P Capital IQ predicted $0.44 per share. Non-GAAP EPS of $0.43 were the same as the prior-year quarter. GAAP EPS of $0.34 for Q2 were 5.6% lower than the prior-year quarter's $0.36 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 53.8%, 60 basis points better than the prior-year quarter. Operating margin was 10.1%, 50 basis points worse than the prior-year quarter. Net margin was 5.0%, 40 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $186.3 million. On the bottom line, the average EPS estimate is $0.40.

Next year's average estimate for revenue is $772.6 million. The average EPS estimate is $1.81.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 32 members out of 48 rating the stock outperform, and 16 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 13 give CONMED a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CONMED is outperform, with an average price target of $35.56.

Is CONMED the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.